TB Research

Evaluation of tuberculosis diagnostic biomarkers in immunocompromised hosts based on cytokine levels in QuantiFERON-TB Gold Plus

Imoto S, Suzukawa M, Takeda K, Motohashi T, Nagase M, Enomoto Y, Kawasaki Y, Nakano E, et al. (16 authors)

Tuberculosis (Edinburgh, Scotland) · 2022-08

Abstract

Tuberculosis (TB) remains a serious health concern globally. QuantiFERON-TB (QFT) is a diagnostic tool for TB detection, and its sensitivity is reduced in immunocompromised hosts with low T lymphocyte counts or abnormal T cell function. This study aimed to evaluate the correlation between T cell and cytokine levels in patients with active TB using QFT-Plus. Forty-five patients with active TB were enrolled, and the cytokines in QFT-Plus tube supernatants were quantified using the MAGPIX System. CD4 + T cell count negatively correlated with patient age (p + T cell count, whereas the levels of TB2-responsive IL-1Ra and IFN-γ-induced protein 10 correlated with both CD4 + and CD8 + T cell counts. Cytokines that correlated with CD4 + and CD8 + T cell counts might not be suitable TB diagnostic biomarkers in immunocompromised hosts. Notably, cytokines that did not correlate with the T cell counts, such as monocyte chemoattractant protein-1, might be candidate biomarkers for TB in immunocompromised hosts. Our findings might help improve TB diagnosis, which could enable prompt treatment and minimize poor disease outcomes.

MeSH terms

  • Humans
  • Mycobacterium tuberculosis
  • Tuberculosis
  • Receptors, Interleukin-1
  • Interleukin-2
  • Cytokines
  • Immunocompromised Host
  • Chemokine CCL2
  • Interleukin 1 Receptor Antagonist Protein
  • Interferon-gamma
  • Latent Tuberculosis
  • Interferon-gamma Release Tests
  • Biomarkers